Singapore, Sept. 11 -- South Korea-based Lunit, a leading provider of AI for cancer diagnostics and precision oncology, has announced that US-based 10x Genomics, Inc. will incorporate Lunit's AI-powered pathology platform, Lunit SCOPE IO, into its oncology biomarker discovery workflow.

Lunit SCOPE IO will be used to analyse Hematoxylin and Eosin (H&E) pathology images alongside spatial molecular data generated from 10x's oncology-focused clinical research studies.

The work brings together molecular insights generated using 10x's Xenium and Atera spatial platforms with tissue characterization from Lunit SCOPE IO. By analszing pathology images alongside spatial molecular data, 10x aims to better understand how tissue morphology relates to...